Long COVID is a recognized post-viral syndrome characterized by neurological, somatic and neuropsychiatric symptoms that might last for long time after
SARS-CoV-2 infection. An ever-growing number of patients come to the observation of General Practitioners complaining of mild or moderate symptoms after the resolution of the acute
infection. Nine General Practitioners from the Rome area (Italy) performed a retrospective analysis in order to evaluate the role of the supplementation with
Palmitoylethanolamide co-ultramicronized with
Luteolin (PEALUT) on neurologic and clinical symptoms reported by their patients after
COVID-19 resolution. Supplementation with PEALUT helped to improve all patient-reported symptoms, especially
pain, anxiety and depression,
fatigue,
brain fog,
anosmia and
dysgeusia, leading to an overall improvement in patients' health status. To our knowledge these are the first data presented on
Long COVID patients collected in a territorial setting. Despite their preliminary nature, these results highlight the pathogenetic role of "non-resolving"
neuroinflammation in
Long COVID development and consequently the importance of its control in the resolution of the pathology and put the focus on the General Practitioner as the primary figure for early detection and management of
Long COVID syndrome in a real-life setting. Future randomized, controlled, perspective clinical trials are needed to confirm this preliminary observation.